ACE-031
A soluble decoy receptor that binds and neutralizes myostatin, increasing muscle mass — studied for muscular dystrophy before trials were paused.
Overview
ACE-031 is a soluble fusion protein that acts as a decoy activin type IIB receptor — binding and neutralizing myostatin and related ligands before they can engage muscle cells. Acceleron Pharma developed it for muscular dystrophy but paused trials due to safety concerns including epistaxis (nosebleeds) and gum bleeding.
Benefits
- Increases muscle mass in trials
- Decreases body fat
- Studied for muscular dystrophy applications
Mechanism of Action
Acts as a decoy receptor — binds and sequesters myostatin and similar TGF-β family ligands, preventing them from engaging endogenous activin receptors on muscle cells.
Dosage (informational only)
- Typical range
- Research-only; trials suspended
- Frequency
- Suspended pending safety review
Acceleron paused development after bleeding-related side effects. Long-term safety profile is unclear.
Side Effects
- Epistaxis (nosebleeds) and gum bleeding observed in trials
- Trials paused due to safety concerns
- Long-term effects unclear
Related peptides
A GHRH analog designed for long-acting stimulation of natural growth hormone production.
A long-acting modified analog of insulin-like growth factor 1 with extended half-life and reduced binding-protein affinity.
A myostatin-binding protein studied for its potential to drive significant muscle hypertrophy by removing the body's natural growth ceiling.